<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.3"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Mol Med</journal-id><journal-id journal-id-type="iso-abbrev">Mol Med</journal-id><journal-title-group><journal-title>Molecular Medicine</journal-title></journal-title-group><issn pub-type="ppub">1076-1551</issn><issn pub-type="epub">1528-3658</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmc">PMC12093704</article-id><article-id pub-id-type="publisher-id">1206</article-id><article-id pub-id-type="doi">10.1186/s10020-025-01206-5</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research</subject></subj-group></article-categories><title-group><article-title>Metformin reverses 5-FU resistance induced by radiotherapy through mediating folate metabolism in colorectal cancer</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes"><name><surname>Wang</surname><given-names>Shuxuan</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Lin</surname><given-names>Yanyan</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Zhao</surname><given-names>Qianqian</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Chen</surname><given-names>Huanliang</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Du</surname><given-names>Shisuo</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Zeng</surname><given-names>Zhaochong</given-names></name><address><email>zeng.zhaochong@zs-hospital.sh.cn</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/013q1eq08</institution-id><institution-id institution-id-type="GRID">grid.8547.e</institution-id><institution-id institution-id-type="ISNI">0000 0001 0125 2443</institution-id><institution>Department of Radiation Oncology, Zhongshan Hospital, </institution><institution>Fudan University, </institution></institution-wrap>Shanghai, 200032 China </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/013q1eq08</institution-id><institution-id institution-id-type="GRID">grid.8547.e</institution-id><institution-id institution-id-type="ISNI">0000 0001 0125 2443</institution-id><institution>Cancer Center, Zhongshan Hospital, </institution><institution>Fudan University, </institution></institution-wrap>Shanghai, 200032 China </aff></contrib-group><pub-date pub-type="epub"><day>21</day><month>5</month><year>2025</year></pub-date><pub-date pub-type="pmc-release"><day>21</day><month>5</month><year>2025</year></pub-date><pub-date pub-type="collection"><year>2025</year></pub-date><volume>31</volume><elocation-id>199</elocation-id><history><date date-type="received"><day>21</day><month>1</month><year>2025</year></date><date date-type="accepted"><day>9</day><month>4</month><year>2025</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2025</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article&#x02019;s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article&#x02019;s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>.</license-p></license></permissions><abstract id="Abs1"><sec><title>Purpose</title><p id="Par1">Radiation therapy has revolutionized the treatment of primary or liver metastases in colorectal cancer (CRC). In colorectal cancer, conventional fractionation (1.8&#x02009;~&#x02009;2.0&#x000a0;Gy daily) is typically used for treatment. Nevertheless, there is a paucity of research investigating the potential implications of radiation therapy-induced alterations in the expression levels of regulatory genes on resistance to chemotherapy agents. Herein, we explored the mechanism by which conventional fractionation drives 5-fluorouracil (5-FU) resistance and metformin (Met) rescued 5-FU resistance in CRC.</p></sec><sec><title>Methods and materials</title><p id="Par2">RNA sequencing, differential genes expression analysis was performed to identify the 5-FU resistance genes after irradiation (according to the convention of cell irradiation, 2&#x000a0;Gy &#x000d7; 8 scheme was selected). Drug sensitivity assay, immunofluorescence staining, folate analogs concentration measurement was used to explore the biological function of histocompatibility minor 13 (HM13) and &#x003b3;-Glutamyl Hydrolase (GGH). Combined chemosensitivity test and xenograft mouse model has been used to gain insights into the underlying clinical value of the combination of 5-FU and Met.</p></sec><sec><title>Results</title><p id="Par3">The conventional fractionation scheme (2&#x000a0;Gy &#x000d7; 8) induced resistance to 5-FU in the CRC cell line HCT-15, accompanied by an elevated RNA expression level of peptidase HM13. Mechanistically, the increased expression of HM13 caused an abnormal shearing of the N-terminal signal peptide of &#x003b3;-Glutamyl Hydrolase (GGH), which resulted in decreased intracellular content of 5, 10-methylenetetrahydrofolate (5,10-CH<sub>2</sub>-THF).</p></sec><sec><title>Conclusion</title><p id="Par4">We revealed a new mechanism of 5-FU resistance induced by irradiated with 2&#x000a0;Gy &#x000d7; 8 through the HM13-GGH-5,10-CH<sub>2</sub>-THF axis. The synergistic effect of Met and 5-FU can rescue 5-FU resistance after conventional fractionated irradiation. In summary, this work will help to reveal the mechanisms of IR-induced 5-FU resistance, which is important for finding new therapeutic targets and improving the efficacy of chemotherapy regimens after radiotherapy.</p></sec><sec><title>Supplementary Information</title><p>The online version contains supplementary material available at 10.1186/s10020-025-01206-5.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Irradiation</kwd><kwd>5-FU</kwd><kwd>Histocompatibility minor 13</kwd><kwd>Metformin</kwd><kwd>Folate metabolism</kwd></kwd-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">https://doi.org/10.13039/501100001809</institution-id><institution>National Natural Science Foundation of China</institution></institution-wrap></funding-source><award-id>82102823</award-id><award-id>82373519</award-id></award-group></funding-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">https://doi.org/10.13039/501100002858</institution-id><institution>China Postdoctoral Science Foundation</institution></institution-wrap></funding-source><award-id>2021M700832</award-id></award-group></funding-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">https://doi.org/10.13039/501100012166</institution-id><institution>National Key Research and Development Program of China</institution></institution-wrap></funding-source><award-id>2022YFC2503704</award-id></award-group></funding-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; The Feinstein Institute for Medical Research 2025</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Introduction</title><p id="Par5">Colorectal cancer (CRC) is a common cancer of the digestive tract that affects older people (Dekker et al. <xref ref-type="bibr" rid="CR1">2019</xref>). The prognosis of CRC has currently been improved following the combination treatment of surgery and neoadjuvant chemotherapy or radiation treatments (Dekker et al. <xref ref-type="bibr" rid="CR1">2019</xref>). However, CRC remains the second greatest cause of cancer-related death globally (Dekker et al. <xref ref-type="bibr" rid="CR1">2019</xref>). Locally advanced CRC is treated with a mix of chemotherapy, surgery, and radiotherapy. Radiotherapy primarily exerts its lethal effects by activating the immune system, altering the tumor microenvironment, modifying cellular metabolic cycles, and impacting DNA damage repair (DDR) mechanisms (McLaughlin et al. <xref ref-type="bibr" rid="CR2">2020</xref>; Du et al. <xref ref-type="bibr" rid="CR3">2021</xref>). Research indicates that there are significant differences in gene expression levels after radiotherapy (Tsai et al. <xref ref-type="bibr" rid="CR4">2007</xref>; Haviland et al. <xref ref-type="bibr" rid="CR5">2013</xref>).</p><p id="Par6">The current standard therapy is based on fluorouracil as monotherapy or combination therapy. Clinically, this class of drugs includes 5-FU, Capecitabine, Tegorio, etc. 5-FU, as a classic drug in the chemotherapy regimen for CRC, has well-documented efficacy in continuous low-dose infusion therapy (Dekker et al. <xref ref-type="bibr" rid="CR1">2019</xref>). However, the current study revealed that adjuvant chemotherapy with 5-FU&#x02009;+&#x02009;leucovorin (LV) after radiotherapy does not enhance the prognosis of locally advanced CRC (Bosset et al. <xref ref-type="bibr" rid="CR7">2014</xref>; Sainato et al. <xref ref-type="bibr" rid="CR8">2014</xref>). Conversely, recent research has shown that 5-FU sensitizes cells to radiation by regulating multiple biological processes which is in sharp contrast to the poor efficacy of 5-FU after radiotherapy (Tsai et al. <xref ref-type="bibr" rid="CR4">2007</xref>; Tang et al. <xref ref-type="bibr" rid="CR9">2017</xref>). However, the reason for the lack of improvement in prognosis when using 5-FU after radiotherapy remains unknown.</p><p id="Par7">5-FU is an uracil analog, it metabolizes within the cell to 5-fluoro-2&#x02019;-deoxyuridylate monophosphate (FdUMP) and forms a ternary complex with 5,10-CH<sub>2</sub>-THF and thymidylate synthase (TS), which blocks 2&#x02032;-deoxyuridine-5&#x02032;-monophosphate (dUMP) from accessing the nucleotide binding site of TS, resulting in an imbalance in the deoxynucleotide triphosphate (dNTP) pool (Longley et al. <xref ref-type="bibr" rid="CR10">2003</xref>). The depletion of deoxythymidine monophosphate (dTMP) promotes the consumption of deoxythymidine triphosphate (dTTP), and disrupts the balance of other dNTPs. This imbalance in the deoxyuridine triphosphate (dNTP) pool impairs DNA synthesis and DDR. The increased deoxyuridine triphosphate (dUTP) and 5-fluoro-2&#x02019;-deoxyuridine triphosphate (5-FdUTP) promote uracil misincorporation into DNA (Longley et al. <xref ref-type="bibr" rid="CR10">2003</xref>).</p><p id="Par8">Since the application of 5-FU to cancer treatment, numerous studies studies have focused on the cause of 5-FU resistance, with any alteration in the constituents of the ternary complex potentially leading to the development of drug resistance (Marsh et al. <xref ref-type="bibr" rid="CR11">2001</xref>). Emerging evidence has increasingly elucidated the critical interplay between metabolic reprogramming, DNA damage repair, and chemoresistance mechanisms, DNA damage repair, and drug resistance (Acharya et al. <xref ref-type="bibr" rid="CR12">2024</xref>). Therefore, we hypothesized that radiotherapy could modulate cellular metabolic pathways and thereby affect chemosensitivity to 5-FU. Depending on how the radiation dose is divided, radiotherapy fractionation schemes are divided into Hypofractionated radiotherapy (HFRT) and Conventional fractionation radiotherapy (CFRT); CFRT (1.8&#x02009;~&#x02009;2.0&#x000a0;Gy per day) is based on the radiobiological characteristics of tumor cells and takes advantage of the repair capacity of normal tissues to reduce toxicity during a long treatment process while ensuring continuous killing of tumor cells (Ahmad et al. <xref ref-type="bibr" rid="CR13">2012</xref>). In the treatment of CRC, conventional fractionation scheme is more widely used. Therefore, we investigated the therapeutic effect of 5-FU after the conventional fractionation schemes and the underlying mechanisms of 5-FU resistance.</p><p id="Par9">Metformin is the first-line medication to treat type 2 diabetes mellitus (T2DM) (Jara and L&#x000f3;pez-Mu&#x000f1;oz <xref ref-type="bibr" rid="CR27">2015</xref>). Furthermore, increasing evidence points towards other diseases that might also have an important role, including cancer, age-related diseases and inflammatory diseases (Jara and L&#x000f3;pez-Mu&#x000f1;oz <xref ref-type="bibr" rid="CR27">2015</xref>). Metformin has been proven in studies to be effective as an adjuvant treatment for CRC (Coyle et al. <xref ref-type="bibr" rid="CR15">2016</xref>). And metformin has been referred to as an &#x0201c;antimetabolite&#x0201d; by certain researchers, implying that it can influence one-carbon metabolism. However, the particular effects of metformin on folate metabolites are unclear.</p><p id="Par10">In our study, using RNA sequencing analysis of HCT-15 cells under different treatment conditions, we screened HM13 that was most upregulated after radiotherapy. Based on the biological characteristics of HM13 as a signal peptide peptidase and Effect of radiotherapy on folate circulation, we identified the only GGH protein carrying an N-terminal signal peptide from the 5-FU metabolic pathway and key enzymes of the folate cycle. And the conventional fractionation scheme (2&#x000a0;Gy &#x000d7; 8) contributed to abnormal expression of HM13, resulting in premature cleavage of the signal peptide of GGH, which causes GGH to remain in the cytoplasm, resulting in reduced levels of the active 5,10-CH<sub>2</sub>-THF. Consequently, the ternary complex composed of 5,10-CH<sub>2</sub>-THF and TS decreases, which eventually leads to 5-FU drug resistance in CRC patients. Based on the fact that metformin can mediate folate circulation, we chose metformin to further explore, and found that the &#x0201c;anti-metabolic effect&#x0201d; of metformin could enhance the cytotoxic effect of 5-FU after radiotherapy, and rescue the 5-FU resistance caused by radiotherapy.</p><p id="Par11">In summary, we discussed potential reasons for the 5-FU resistance following radiotherapy. and revealed that the HM13-GGH-5,10-CH<sub>2</sub>-THF axis can influence the cytotoxicity of 5-FU. We also proposed a protocol for combination therapy of Met with 5-FU to overcome 5-fu resistance. Our findings additionally advance our understanding of the mechanism of chemotherapy resistance after radiotherapy, but also provide an important theoretical foundation for optimizing clinical radiotherapy regimens and selecting adjuvant chemotherapy after radiotherapy.</p></sec><sec id="Sec2"><title>Materials and methods</title><sec id="Sec3"><title>Cell culture</title><p id="Par12">Human CRC cell lines HCT-15 (RRID: CVCL_0292) and HT-29 (RRID: CVCL_0320), and human embryonic kidney cell line 293T (HEK 293T (RRID: CVCL_0063)), were purchased from the Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences (Shanghai, China). HCT-15 cells were cultured in RPMI 1640 medium (Gibco, USA) supplemented with 10% fetal bovine serum (FBS) (Sigma, Germany), 100 U/ml penicillin-streptomycin (NCM Biotech, China). HT-29 cells were cultured in McCoy&#x02019;s 5&#x000a0;A medium (Gibco, USA) with 10% FBS (Sigma, Germany), 100 U/ml penicillin-streptomycin (NCM Biotech, China). The 293T cells were cultured in DMEM medium supplemented with 10% FBS (Sigma, Germany), 100 U/ml penicillin-streptomycin (NCM Biotech, China). All cells were incubated at 37&#x000a0;&#x000b0;C in a humidified atmosphere containing 5% CO<sub>2</sub>. Mycoplasma contamination was regularly tested in all cell cultures. All cell lines were authenticated using short tandem repeat (STR) profiling within the last 3 years. All experiments were performed with mycoplasma-free cells.</p><p id="Par13">Construction of the HCT-15/5-FU and HCT-15/L-OHP Cell Line. The human CRC 5-FU-resistant cell line HCT-15/5-FU was established using a continuous stepwise drug concentration increment method with 5-FU. This cell line stably grows in RPMI 1640 medium containing 20 &#x000b5;M 5-FU, exhibiting RI (resistance index) of 10.4. The human CRC L-OHP-resistant cell line HCT-15/L-OHP was established using a continuous stepwise drug concentration increment method with L-OHP. This cell line stably grows in RPMI 1640 medium containing 20 &#x000b5;M 5-FU, exhibiting RI (resistance index) of 12.5.</p></sec><sec id="Sec4"><title>mRNA sequencing experimental method</title><p id="Par14">Detailed mRNA sequencing experimental method is available in the Supplemental Materials.</p><p id="Par15">The sequencing coverage and quality statistics for each sample are summarized in Supplementary Table <xref rid="MOESM1" ref-type="media">S1</xref>.</p></sec><sec id="Sec5"><title>Construction of overexpression and knockdown cell lines</title><p id="Par16">The designed of sgRNA sequences was based on the protocol from Zhang&#x02019;s laboratory, with the following target sequences for CRISPR-Cas9 single-guide RNAs (sgRNAs):</p><p id="Par17">sgHM13: 5&#x02019;- GATGTCAAAGCGCAGCAGCA-3&#x02019;.</p><p id="Par18">sgGGH-1: 5&#x02019;- TGCGTCCTATGTAAAGTACT-3&#x02019;.</p><p id="Par19">sgGGH-2: 5&#x02019;- TGACTGCCAATTTCCATAAG-3&#x02019;.</p><p id="Par20">We used CRISPR-Cas9 system to knockout HM13 and GGH genes. The LentiCRISPR v2 plasmid was used to construct vectors along with packaging plasmids, and 293T cells were infected. HCT-15 and HT-29 cells were infected, and 48&#x000a0;h post-infection, cells were selected using 1&#x000a0;&#x000b5;g/ml puromycin.</p><p id="Par21">The coding sequences of HM13, GGH, and the GGH mutant lacking the N-terminal signal peptide were cloned into the pGV348-HA vector. Following lentiviral packaging, the constructs were used to infect HCT-15 and HT-29 cells. Infected cells were selected with 1&#x000a0;&#x000b5;g/ml puromycin 48&#x000a0;h post-infection.</p></sec><sec id="Sec6"><title>RNA extraction and reverse transcription quantitative PCR analysis</title><p id="Par22">Total RNA was extracted by MolPure<sup>&#x000ae;</sup> Cell RNA Kit (Cat. 19231, Yeasen, China) and reverse transcribed (RT) to cDNA using Hifair<sup>&#x000ae;</sup> AdvanceFast One-step RT-gDNA Digestion SuperMix for qPCR (Cat. 11151, Yeasen, China). Quantitative PCR (qPCR) reactions were carried out with qPCR SYBR Green Master Mix (No Rox) (Cat. 11201, Yeasen, China). Relative mRNA expression levels were normalized to ACTB.</p><p id="Par23">Primers used included:</p><p id="Par24">HM13,</p><p id="Par25">F-CTGGTACCTGCTGAGGAAGC</p><p id="Par26">R-GGTGCCAAATACCCAGAAGA</p><p id="Par27">GGH,</p><p id="Par28">F<sub>&#x02212;&#x00394;N</sub>-TCCTTTTCCCTGGAGGAAGT</p><p id="Par29">F-TCTGGAACATTCTGCTGTGC</p><p id="Par30">R-GTGCTGGGCCTGCTACTCT</p><p id="Par31">ACTB,</p><p id="Par32">F-CATCCGCAAAGACCTGTACG</p><p id="Par33">R-CCTGCTTGCTGATCCACATC</p></sec><sec id="Sec14"><title>Western blot analysis</title><p id="Par34">Primary antibodies used for western blot were: HM13 (ab190253, Abcam, UK), GGH (13264-1-AP, Proteintech, USA), GAPDH (60004-1-Ig, Proteintech, USA), ACTIN (66009-1-Ig, Proteintech, USA), LAMP-2 (SC-18822, Santa Cruz, USA), Tubulin (10068-1-AP, Proteintech, USA). Secondary antibodies used for western blot were: HRP-conjugated Goat anti-Rabbit/Mouse IgG (A0208/A0216, Beyotime, China). Enhanced chemiluminescence (ECL) reagent (WBKLS0500, Millipore, USA). The band quantification was measured by ImageJ software (NIH).</p></sec><sec id="Sec15"><title>Cell viability assay</title><p id="Par35">5,000 cells were seeded in each well of 96-well plates and treated for 72&#x000a0;h with gradient concentration of 5-FU, and cell viability was measured by the CellTiter-Glo Luminescent Kit (Cat. G7573, Promega, USA). The half-maximal inhibitory concentration (IC<sub>50</sub>) was then calculated by GraphPad Prism 8.0.2. Each experiment was performed in triplicate, and results were expressed as mean&#x02009;&#x000b1;&#x02009;SD.</p><p id="Par36">To determine the combined drug treatment effects and calculate synergy efficiency, cells were treated with 5-FU at concentrations of 0, 1, 3, 10, 30, 100, 300 and 1000 &#x000b5;M, with or without Met at concentrations of 0, 0.5, 1, 2, 5, 10 and 20 mM. The HSA mode synergy score was calculated using the SynergyFinder web application to evaluate the synergistic effects.</p></sec><sec id="Sec16"><title>Immunofluorescence staining</title><p id="Par37">HCT-15 cells subjected to irradiation treatment were cultured on coverslips, then fixed with ice-cold methanol for 5&#x000a0;min, and permeabilized with 0.1% Triton X-100. The cells were blocked with 1% bovine serum albumin in PBS for 1&#x000a0;h, followed by antibody staining (anti-GGH antibody, 1:200; anti-LAMP-2 antibody, 1:200). Alexa Fluor 488-conjugated goat anti-mouse IgG and Alexa Fluor 647-conjugated goat anti-mouse IgG were used as secondary antibodies. After washing with PBS, the cells were mounted with DAPI-containing ProLong Gold antifade reagent. Analysis was performed using an SP5 confocal microscope.</p></sec><sec id="Sec17"><title>Cell irradiation experiment</title><p id="Par38">Cells in the logarithmic growth phase were irradiated using the ONCOR&#x02122; linear accelerator (Siemens, Munich, Germany) with 2&#x000a0;Gy &#x000d7; 8 of X-ray irradiation.</p></sec><sec id="Sec18"><title>ELISA detection</title><p id="Par39">The Methionine, SAH, SAM and Homocysteine content were measured using the Methionine ELISA kit (QEK13852, Biogradetech, USA), SAH ELISA kit (QEK04333, Biogradetech, USA), SAM ELISA kit (QEK01036, Biogradetech, USA) and Homocysteine ELISA kit (CSB-E13814h, CUSABIO, China), following the manufacturer&#x02019;s instructions.</p></sec><sec id="Sec19"><title>Signal peptidase site prediction</title><p id="Par40">Key gene clusters in the 5-FU metabolic and folate metabolism pathway were selected, and predictions of signal peptidase sites were analyzed using the SignalP 6.0 web application: all protein sequences were imported into SignalP 6.0 (fasta format) and analyzed under the following conditions: Organism: Eukarya; Output format: Long output; Model mode: Fast. Analysis of signal peptide positions (CS positions) based on the output prediction results (Teufel et al. <xref ref-type="bibr" rid="CR16">2022</xref>).</p></sec><sec id="Sec20"><title>Intracellular folate and folate analogs concentration measurement</title><p id="Par41">Cells were collected and resuspended in 500 &#x000b5;L of 95% methanol/extraction buffer (75 mM KH<sub>2</sub>PO<sub>4</sub>, 0.4&#x000a0;M ascorbic acid, 0.8% 2-mercaptoethanol, pH 6.0). After vortexing for 1&#x000a0;min, the samples were ground at 65&#x000a0;Hz for 300&#x000a0;s and sonicated at 4&#x000a0;&#x000b0;C for 30&#x000a0;min, then allowed to stand for 1&#x000a0;h. The supernatant was dried by a rotary evaporator after centrifugation at 12,000 &#x000d7; rpm for 15&#x000a0;min at 4. The residue was resuspended in 100 &#x000b5;L of 95% methanol/extraction buffer. And the supernatant was measured by liquid chromatography on Waters Acquity UPLC and mass spectrometry by AB SCIEX 5500 Qtrap-MS. Folate, 5,10-CH<sub>2</sub>-THF and 5-methyl-tetrahydrofolate (5-CH<sub>3</sub>-THF) concentrations were calculated using MultiQuant software and standard curves.</p><p id="Par42">The concentration of folic acid analogue polyglutamated metabolite was determined using peak area analysis, following the protocol by Lee C. Garratt (Garratt et al. <xref ref-type="bibr" rid="CR17">2005</xref>).</p></sec><sec id="Sec21"><title>Xenograft mouse model</title><p id="Par43">6-8-week-old male nude mice were used and housed in a pathogen-free environment. HCT-15 cells (5&#x02009;&#x000d7;&#x02009;10<sup>6</sup>) were subcutaneously implanted into the mice&#x02019;s right flank., mice were irradiated at 2 Gy &#x000d7; 8 when tumors reached a volume of 100&#x000a0;mm (Du et al. <xref ref-type="bibr" rid="CR3">2021</xref>).which were then randomly separated into four groups (DMSO, Met, 5-FU, Met&#x02009;+&#x02009;5-FU). 5-FU (20&#x000a0;mg/kg), Met (100&#x000a0;mg/kg), or both drugs combined were intraperitoneally injected into mice every other day after irradiation, the tumor volumes were monitored with calipers every two day. And the tumor volumes were calculated by the formula: 1/2 length &#x000d7; width<sup>2</sup>. Tumors were harvested for western blot analysis on day 30 post-irradiation (the tumor volume&#x02009;&#x0003c;&#x02009;1000&#x000a0;mm (Du et al. <xref ref-type="bibr" rid="CR3">2021</xref>).</p></sec><sec id="Sec22"><title>Statistical analysis</title><p id="Par44">The statistical analysis was conducted by GraphPad Prism 8.0 software. Data were shown as the mean&#x02009;&#x000b1;&#x02009;SD, and three independent experiments were performed. In the xenograft mouse model, each experimental group comprised 6 mice, to mitigate potential outliers, the maximum and minimum tumor volume values within each group were excluded prior to statistical analysis. A two-tailed Student&#x02019;s t-test was used to compare group means. Survival curve analysis was analyzed using two-way ANOVA, *<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.05, **<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.01, ***<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.001, ****<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.0001.</p></sec></sec><sec id="Sec23"><title>Results</title><sec id="Sec24"><title>IR significantly up-regulated the mRNA expression of HM13 in CRC</title><p id="Par45">We constructed a CRC cell model of conventional fractionated sheme of radiotherapy (2&#x000a0;Gy &#x000d7; 8 regimens) (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>A). Drug resistance testing with commonly used chemotherapeutic drugs conducted after irradiation revealed that the half-maximal inhibitory concentration (IC<sub>50</sub>) value of 5-FU and other similar metabolic drugs increased significantly at 48&#x000a0;h post-irradiation (short-term, ST) and after long-term culture (over 2 months), the inhibition rate of other commonly used chemotherapy drugs did not change significantly (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>A-B, Fig <xref rid="MOESM1" ref-type="media">S1</xref>A-C). And 5-FU-resistant CRC cell lines may develop cross-resistance to oxaliplatin (L-OHP&#x0200c;&#x0200c;), we constructed L-OHP&#x0200c;&#x0200c; resistant cell lines (HCT-15/L-OHP&#x0200c;&#x0200c;) and 5-FU resistant cell lines (HCT-15/5-FU) of CRC, and performed RNA-seq to identify the resistance genes responsible for 5-FU resistance only affected by radiotherapy (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>C-D, Fig <xref rid="MOESM1" ref-type="media">S1</xref>A-C).</p><p id="Par46">
<fig id="Fig1"><label>Fig. 1</label><caption><p> IR significantly up-regulated the mRNA expression of HM13 in CRC (<bold>A</bold>) Scheme for the treatment of the HCT-15 cell line. HCT-15 cells were subjected to irradiation with 2 Gy &#x000d7; 8. Cells were collected for analysis at two time points: after short-term culture (48&#x000a0;h post-irradiation, short-term: 2 Gy &#x000d7; 8 ST) and after long-term culture (2 months post-irradiation, long-term: 2 Gy &#x000d7; 8). (<bold>B</bold>) The heatmap based on the IC<sub>50</sub> of response to 5-FU, 5-FU&#x02009;+&#x02009;LV, Tegafur, Capecitabine, Oxaliplatin, Irinotecan, Cisplatin, and Gemcitabine in various HCT-15 (Left) or HT-29 (Right) cells. (<bold>C-D</bold>) Scheme of 5-FU-resistant (<bold>C</bold>) or L-OHP-resistant (<bold>D</bold>) cell line construction. HCT-15 cells were cultured in medium containing 20 &#x000b5;M 5-FU (<bold>C</bold>) or 20 &#x000b5;M L-OHP (<bold>D</bold>). The medium was replaced with 5-FU-free medium or L-OHP-free medium every 48&#x000a0;h for buffering. This process was repeated continuously for 6 months, and RI (5-FU-resistant)&#x02009;=&#x02009;10.4. RI (L-OHP-resistant)&#x02009;=&#x02009;12.5. (<bold>E</bold>) Statistic of DEGs using RNA-seq data from four experimental groups, <bold>A</bold>: sham IR group (0&#x000a0;Gy); <bold>B</bold>: IR group (2 Gy &#x000d7; 8); <bold>C</bold>: L-OHP-resistant group; <bold>D</bold>: 5-FU resistance group. And q-value&#x02009;&#x0003c;&#x02009;0.05, |log<sup>2</sup>FC| &#x0003e; 1.0. (<bold>F</bold>). Venn of shared and specific DEGs between different groups. (<bold>G</bold>). The heatmap based on the RNA-SEQ results of 1B. (<bold>H</bold>). The mRNA expression level of HM13 in sham IR, IR and HCT-15/5-FU groups. (<bold>I</bold>). The mRNA expression level of HM13 in sham IR and 48&#x000a0;h post-IR. (<bold>J</bold>). Survival analysis using Kaplan-Meier Plotter web software. Kaplan-Meier Plot analysis demonstrating the prognostic association of HM13 expression with OS in patients with CRC. The log rank test was performed to compare high and low HM13 expression groups. Univariate Cox regression was used to calculate the hazard ratio (HR) and its related 95% confidence interval. (<bold>K</bold>). Differential expression of HM13 across pan-cancer analyzed using SangerBox. *<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.05, ****<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.0001</p></caption><graphic xlink:href="10020_2025_1206_Fig1_HTML" id="d33e549"/></fig>
</p><p id="Par47">To explore the potential contribution of irradiation in 5-FU resistance, we initially examined the differential gene expression by using RNA sequencing (RNA-seq) analysis in CRC cell lines irradiated (2&#x000a0;Gy &#x000d7; 8) and on 5-FU or L-OHP resistance cell lines: sham IR control (Group A), IR (Group B), L-OHP-resistant cell (Group C), and 5-FU-resistant cells (Group D).</p><p id="Par48">We identified 566 genes (increased) and 236 genes (decreased) after IR (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>E). The Venn diagram was used to show the common differentially expressed genes (DEGs) between B and A, B and C, D and A. 41 (16&#x02009;+&#x02009;25) genes were found. (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>F). To focus on specific effects of 5-FU resistance (L-OHP cross resistance was excluded) caused by IR, we excluded 25 DEGs for A vs. D, resulting in 16 unique genes that were annotated by heat maps. (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>F-G). The mRNA level of HM13 increased the most in IR group compared with the sham IR group (H). HM13 is an important signal peptide peptidase that affects the maturation and activity of many proteins with N-terminal signal peptides, and its critical involvement in metabolic cycles, we selected HM13 for further investigation (Mentrup et al. <xref ref-type="bibr" rid="CR18">2020</xref>). In addition, the mRNA expression level of HM13 was significantly up-regulated in IR ST group, IR group and the 5-FU-resistant group, which is a potential 5-FU resistance gene (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>H-I).</p><p id="Par49">Considering the up-regulated expression of HM13 in CRC, we further investigated its relationship with the prognosis of CRC using the Kaplan-Meier plotter (Gyorffy <xref ref-type="bibr" rid="CR19">2024</xref>). The HM13 high expression group had shorter overall survival (OS) than the low expression group (hazard ratio&#x02009;=&#x02009;1.41, <italic>P</italic>&#x02009;=&#x02009;0.0064) (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>J). We discovered that HM13 expression was remarkably upregulated in most cancer types by TCGA database and GTEx database analyzing with the SangerBox 3.0 web software (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>K) (Shen et al. <xref ref-type="bibr" rid="CR20">2022</xref>).</p></sec><sec id="Sec25"><title>The increase of HM13 expression level elicits the 5-FU-resistance after IR</title><p id="Par50">Our result showed that when exposed to IR, both short-term and long-term HM13 protein expression levels increased (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>A). However, the irradiation only affected the cell proliferation level in the short term. (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>B, S2A).</p><p id="Par51">
<fig id="Fig2"><label>Fig. 2</label><caption><p> The increase of HM13 expression level elicits the 5-FU-resistance after IR. (<bold>A</bold>) Endogenous HM13 protein expression in IR group and sham IR group. (<bold>B</bold>) Growth curves of IR groups and sham IR groups. The means&#x02009;&#x000b1;&#x02009;SD are used to display the data. (<bold>C</bold>) Endogenous HM13 protein expression in HCT-15 cells. (<bold>D-E</bold>) Cell viability with 5-FU exposure in mock and sgHM13 HCT-15 cells by IR, the dose&#x02013;response curve: <bold>D</bold>; the bar graph of IC<sub>50</sub> values: <bold>E</bold>. (<bold>F</bold>) Overexpression of HM13 in HCT-15 cells. (<bold>G-H</bold>) Cell viability with 5-FU exposure in parental and exogenous overexpression of HM13 HCT-5 cells, the dose&#x02013;response curve: <bold>G</bold>; the bar graph of IC<sub>50</sub> values: <bold>H</bold>. (<bold>I</bold>) Endogenous HM13 protein expression in irradiated HCT-15 cells (2&#x000a0;Gy &#x000d7; 8) exposure to the inhibitor of HM13, (Z-LL)<sub>2</sub> Ketone. (<bold>J-K</bold>) Cell viability with 5-FU exposure in HM13-inhibited HCT-15 cells, the dose&#x02013;response curve: <bold>J</bold>; the bar graph of IC<sub>50</sub> values: <bold>K</bold>. All figures were representatives of three independent experiments. Error bars represent the SD. ****<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.0001, two-tailed Student&#x02019;s t-test</p></caption><graphic xlink:href="10020_2025_1206_Fig2_HTML" id="d33e662"/></fig>
</p><p id="Par52">Additionally, HM13 knockout partially rescued the resistance to 5-FU induced by IR (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>C-E, S2B-C). And overexpression of HM13 in sham IR also resulted in the development of 5-FU resistance (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>F-H, S2D-E). Thus, we propose that increased HM13 protein expression is a critical factor in the development of 5-FU resistance.</p><p id="Par53">To further elucidate the impact of HM13 protein on 5-FU resistance, we used the HM13 inhibitor (Z-LL)<sub>2</sub> Ketone. Similar to the results in Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>F, the addition of (Z-LL)<sub>2</sub> Ketone to inhibit HM13 protein function after IR partially rescued the cells from 5-FU resistance (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>I-K, S2F-G). Overall, the results show that that HM13 knockout does not sensitize cells to 5-FU, only shows the resistance caused by increased expression.</p><p id="Par54"><bold>HM13 cleaves the signal peptide</bold>,<bold> resulting in changes in GGH localization and protein function.</bold></p><p id="Par55">As a crucial signal peptide peptidase, HM13 cleaves the signal sequences (SSs) of secretory precursors, playing an essential role in their maturation (Mentrup et al. <xref ref-type="bibr" rid="CR18">2020</xref>). Given the significant 5-FU resistance observed following IR, we used SignaIP 6.0 web software to identify key enzymes in the 5-FU-related metabolic pathway and the 5,10-CH<sub>2</sub>-THF cycle (Fig S3A) (Longley et al. <xref ref-type="bibr" rid="CR10">2003</xref>; Teufel et al. <xref ref-type="bibr" rid="CR16">2022</xref>; Raz et al. <xref ref-type="bibr" rid="CR21">2016</xref>). We found that only GGH carries a signal peptide and associates with sec/spi (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>A, S3B).</p><p id="Par56">
<fig id="Fig3"><label>Fig. 3</label><caption><p> HM13 cleaves the signal peptide, resulting in changes in GGH localization and protein function. (<bold>A</bold>) The binding sites of the GGH gene sequence with signal peptidase were predicted using SignalP 6.0 prediction analysis. (<bold>B</bold>) GGH protein expression in HCT-15 cells. (<bold>C</bold>) GGH protein expression in HM13-knockdown HCT-15 cells. KD: knockdown. (<bold>D</bold>) Schematic diagram of GGH protein domain. (<bold>E</bold>) The total proteins, the proteins localized in lysosomes, the proteins localized in cytoplasm and nucleus were collected by Lysosome isolation experiment. Expression of GGH protein in the lysosomes and cytoplasm of IR group, IR&#x02009;+&#x02009;HM13<sup>KD</sup> group and sham IR group. (<bold>F</bold>) Localization of GGH protein in IR group, IR&#x02009;+&#x02009;HM13<sup>KD</sup> group and sham IR group. Red: lysosome; Green: GGH; Blue: DNA. (<bold>G-I</bold>) Levels of 5,10-CH<sub>2</sub>-THF polyglutamated metabolites (5,10-CH<sub>2</sub>-H<sub>4</sub>PteGlu<sub>n</sub>) in various HCT-15 cells. Various types of 5,10-CH<sub>2</sub>-H<sub>4</sub>PteGlu<sub>n</sub> (<bold>G</bold>); Total 5,10-CH<sub>2</sub>-H<sub>4</sub>PteGlu (<bold>H</bold>); Proportion analysis of various types of 5,10-CH<sub>2</sub>-H<sub>4</sub>PteGlu (<bold>I</bold>). (<bold>J-K</bold>) Multiple gradient folic acid supplementation (maximum concentration 5 mM, 3&#x000d7;gradient dilution) after folic acid deprivation in the various tested groups. Folate growth requirement of IR group, IR&#x02009;+&#x02009;HM13<sup>KD</sup> group and sham IR group, the dose&#x02013;response curve: <bold>J</bold>; the bar graph of IC<sub>50</sub> values: <bold>K</bold>. (<bold>L-M</bold>) Cell viability with 5-FU or 5-FU&#x02009;+&#x02009;5,10-CH<sub>2</sub>-THF exposure in various HCT-15 cells, the dose&#x02013;response curve: <bold>L</bold>; the bar graph of IC<sub>50</sub> values: <bold>M</bold>. All figures were representatives of three independent experiments. Error bars represent the SD. ****<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.0001; ns: not significant, two-tailed Student&#x02019;s t-test</p></caption><graphic xlink:href="10020_2025_1206_Fig3_HTML" id="d33e809"/></fig>
</p><p id="Par57">GGH, a key enzyme in the folate metabolism pathway, hydrolyzes polyglutamate tails, reducing intracellular folate pool by converting folate and its derivatives into monomeric forms for cellular export (Wang et al. <xref ref-type="bibr" rid="CR22">2022</xref>). Further, compared with sham IR group, the GGH protein band position in IR group moved down (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>B). It was unexpected to discover that knockdown HM13 after IR caused a significant upward shift in the GGH protein band (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>C). Previous studies have shown that deletion of the N-terminal signal peptide of GGH leads to a downward shift in the GGH protein band (Yao et al. <xref ref-type="bibr" rid="CR23">1996a</xref>, <xref ref-type="bibr" rid="CR24">b</xref>).We selected appropriate fragments of the signal peptide sequence as the special Forward Primer (F<sub>&#x02212;&#x00394;N</sub>), and picked two Primer sequences in CDS regions (F, R), which were combined as F<sub>&#x02212;&#x00394;N</sub> +R and F&#x02009;+&#x02009;R. We confirmed that GGH signaling peptide fragments are still present when transcribed (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>D, Fig S4A-C). In general, the loss of signal peptides occurs during the post-translational modification phase.</p><p id="Par58">To confirm changes in GGH protein localization and function, we conducted lysosome isolation experiments. After IR, GGH protein mainly gathered in vitro of lysozyme, while in HM13-knockdown after IR (IR&#x02009;+&#x02009;HM13<sup>KD</sup>) and sham IR groups, GGH protein was primarily localized within the lysosome. (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>E). Immunofluorescence confirmed the altered localization of GGH protein following IR (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>F).</p><p id="Par59">We measured the concentrations of polyglutamated folate forms (PteGlu<sub>n</sub>) and 5,10-CH<sub>2</sub>-THF in cells irradiated or IR&#x02009;+&#x02009;HM13<sup>KD</sup>, and discovered that the concentrations of PteGlun and 5,10-CH<sub>2</sub>-THF decreased more rapidly as the number of polyglutamate tails increased after IR, whereas in cells irradiated with IR&#x02009;+&#x02009;HM13KD, the concentrations remained unchanged (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>G-I, Fig S5A-C). Using methotrexate (MTX) as an exogenous folate analog, we assessed the function of GGH in hydrolyzing polyglutamate tails post-IR. The intracellular levels of polyglutamated MTX, especially those with 5&#x02013;6 glutamate tails, significantly decreased in IR group (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>D-F). Using the HM13 inhibitor (Z-LL)<sub>2</sub> Ketone, we assessed the ability of GGH to hydrolyze polyglutamate tails and found that the hydrolytic ability was decreased. This finding appears to be inconsistent with the HM13 knockdown results, and the underlying mechanism remains unclear. We speculate that this discrepancy may be attributed to either (Z-LL)<sub>2</sub> Ketone&#x02019;s unique pharmacological actions or compensatory regulatory pathways that were activated in response to HM13 modulation. (Fig S5G-I).</p><p id="Par60">Cell folate dependency is enhanced due to the reduction of the cellular folate pool, indicating increased GGH protein activity (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>J-K, Fig S6A-B). Supplementing with 5,10-CH<sub>2</sub>-THF to increase cellular folate pool partially rescued the 5-FU resistance induced by IR. In contrast, adding 5,10-CH<sub>2</sub>-THF to sham IR group or IR&#x02009;+&#x02009;HM13<sup>KD</sup> group did not decrease the IC<sub>50</sub> of 5-FU, this indicates that the folate pool may be saturated and unable to further increase the levels of 5,10-CH<sub>2</sub>-THF, thereby not significantly enhancing the formation of the ternary complex or cytotoxicity (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>L-M).</p></sec><sec id="Sec26"><title>Loss of the signal peptide in GGH leads to reduced cellular folate pool and 5-FU-resistance</title><p id="Par61">Previous studies have shown that GGH is N-glycosylated when overexpressed directly, whereas removal of the signal peptide results in the loss of glycosylation side chains, which decreases intracellular folate pool, leading to folate-resistance (Wang et al. <xref ref-type="bibr" rid="CR22">2022</xref>). We designated the GGH protein lacking the N-terminal signal peptide as &#x0201c;GGH<sub>&#x02212;&#x00394;N</sub>.&#x0201d; GGH<sub>&#x02212;&#x00394;N</sub> elicits the 5-FU resistance of HCT-15 (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>A-C). Moreover, using exogenous MTX as a folate analog to assess the hydrolytic capability of GGH<sub>&#x02212;&#x00394;N</sub>, we observed enhanced hydrolysis of polyglutamate tails (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>D). Therefore, we hypothesized that the resistance to 5-FU because of the enhanced hydrolysis ability of GGH, resulting in a decrease of the concentration of 5,10-CH<sub>2</sub>-THF.</p><p id="Par62">
<fig id="Fig4"><label>Fig. 4</label><caption><p> Loss of the signal peptide in GGH leads to reduced cellular folate pool and 5-FU-resistance. (<bold>A</bold>) GGH and GGH<sub>&#x02212;&#x025b3;N</sub> overexpression in HCT-15 cells. (<bold>B-C</bold>) Cell viability with 5-FU exposure in various GGH stable expressions of HCT-15 cells, the dose&#x02013;response curve: B; the bar graph of IC<sub>50</sub> values: <bold>C</bold>. (<bold>D</bold>) Levels of MTX-polyglutamated metabolites in various GGH overexpression HCT-15 cells. (<bold>E-F</bold>) Folate growth requirements of various GGH stable expression HCT-15 cells, the dose&#x02013;response curve: <bold>E</bold>; the bar graph of IC<sub>50</sub> values: <bold>F</bold>. (<bold>G</bold>) Levels of 5,10-CH<sub>2</sub>-THF polyglutamated metabolites (5,10-CH<sub>2</sub>-H<sub>4</sub>PteGlu<sub>n</sub>) in various GGH overexpression HCT-15 cells. (<bold>H-I</bold>) Cell viability with 5-FU or 5-FU&#x02009;+&#x02009;5,10-CH<sub>2</sub>-THF exposure in various GGH HCT-15 cells, the dose&#x02013;response curve: <bold>H</bold>; the bar graph of IC<sub>50</sub> values: <bold>I</bold>. (<bold>J</bold>) GGH protein expression in HCT-15 cells. (<bold>K-L</bold>) Cell viability with 5-FU exposure in HCT-15 cells, the dose&#x02013;response curve: <bold>K</bold>; the bar graph of IC<sub>50</sub> values: <bold>L</bold>. All figures were representatives of three independent experiments. Error bars represent the SD. ****<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.0001; ns: not significant., two-tailed Student&#x02019;s t-test</p></caption><graphic xlink:href="10020_2025_1206_Fig4_HTML" id="d33e990"/></fig>
</p><p id="Par63">Furthermore, cells expressing GGH without the signal peptide exhibited increased dependence on folate, indicating reduced intracellular folate pool (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>E-F). And we measured the concentrations of 5,10-CH<sub>2</sub>-THF within the cells overexpressing GGH<sub>&#x02212;&#x00394;N</sub> and discovered that the results were consistent with the high expression of HM13 (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>G). Drug sensitivity assays with 5,10-CH<sub>2</sub>-THF supplementation showed that increasing cellular folate levels could partially rescue 5-FU resistance when GGH lacked the signal peptide, consistent with the results shown in Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>L (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>H-I).</p><p id="Par64">Moreover, the cellular folate pool of HCT-15 cells with GGH knockdown was not significantly increased upon 5-FU treatment. Likewise, the hydrolytic capacity of polyglutamated folate analogs remained unchanged. This indicates the existence of other polyglutamate hydrolases in the cell (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>J-L, S6C-E).</p></sec><sec id="Sec27"><title>Met enhances the cytotoxic effect of 5-FU by mediating cellular folate pool</title><p id="Par65">Studies manifested that Met impairs cellular one-carbon metabolism in a manner similar to the antifolate drugs, leading to the accumulation of folate pathway metabolites, and reducing one-carbon unit transfer in the folate cycle, thereby decreasing purine biosynthesis (Corominas-Faja et al. <xref ref-type="bibr" rid="CR25">2012</xref>; Janzer et al. <xref ref-type="bibr" rid="CR26">2014</xref>). Our LC-MS analysis revealed using Met significantly increased the biosynthesis of 5,10-CH<sub>2</sub>-THF and 5-CH<sub>3</sub>-THF (Fig.&#x000a0;<xref rid="Fig5" ref-type="fig">5</xref>A-B). Furthermore, Met significantly reduced intracellular inosine monophosphate (IMP) concentration (Fig.&#x000a0;<xref rid="Fig5" ref-type="fig">5</xref>C). Indeed, the cytotoxic effects of Met could be effectively rescued by HX supplementation, indicating a decrease in purine biosynthesis which is consistent with previous studies (Fig.&#x000a0;<xref rid="Fig5" ref-type="fig">5</xref>D-E) (Corominas-Faja et al. <xref ref-type="bibr" rid="CR25">2012</xref>; Jara and Lopez-Munoz <xref ref-type="bibr" rid="CR27">2015</xref>). The current study revealed that Met disturbs the homeostasis of the folic acid cycle in C. elegans, leading to the increasing levels of 5-CH<sub>3</sub>-THF and 5,10-CH<sub>2</sub>-THF, while decreasing THF levels (Cabreiro et al. <xref ref-type="bibr" rid="CR28">2013</xref>). Moreover, it can increase SAM and SAH levels while decreasing methionine levels by blocking methionine synthase (MS). We validated this finding in HCT-15 cells, elucidating the mechanism of action of 5-FU and Met in the treatment of colon cancer (Fig S7A-E).</p><p id="Par66">
<fig id="Fig5"><label>Fig. 5</label><caption><p> Met enhances the cytotoxic effect of 5-FU by increasing cellular folate pool. (<bold>A-C</bold>) The levels of 5,10-CH<sub>2</sub>-THF, 5-CH<sub>3</sub>-THF and IMP in HCT-15 cells were measured following treatment with 5-FU, Met, or 5-FU&#x02009;+&#x02009;Met. (<bold>D-E</bold>) Cell viability with Met or Met&#x02009;+&#x02009;Hypoxanthine (100&#x000b5;M) exposure in IR group, the dose&#x02013;response curve: <bold>D</bold>; the bar graph of IC<sub>50</sub> values: <bold>E</bold>. (<bold>F-I</bold>) Cell viability with 5-FU exposure in medium containing Met (0.5 mM) in IR group or GGH<sub>&#x02212;&#x025b3;N</sub> stable expressions of HCT-15 cells., the dose&#x02013;response curve: <bold>F, H</bold>; the bar graph of IC<sub>50</sub> values: <bold>G, I</bold>. (<bold>J-K</bold>) The combined treatment of 5-FU (0, 1, 3, 10, 30, 100, 300 and 1000 &#x000b5;M) and Met (0, 0.5, 1, 2, 5, 10 and 20 mM) were assessed in the irradiation group (2&#x000a0;Gy &#x000d7; 8) HCT-15 cells. The HSA synergy scores was visualized using the SynergyFinder. (<bold>L-M</bold>) HCT-15 cells after irradiated 2&#x000a0;Gy &#x000d7; 8 using/nonusing 5-FU, Met, 5-FU&#x02009;+&#x02009;Met, were subjected to colony formation assay (<bold>L</bold>), quantification data (<bold>M</bold>), <italic>n</italic>&#x02009;=&#x02009;3. (<bold>N-O</bold>) HCT-15 cells after irradiated 2&#x000a0;Gy &#x000d7; 8 using/nonusing 5-FU, Met, 5-FU&#x02009;+&#x02009;Met, were subjected to wound healing assay (<bold>O</bold>) and results were quantified (<bold>N</bold>), <italic>n</italic>&#x02009;=&#x02009;3. All figures were representatives of three independent experiments. Error bars represent the SD, ns: not significant; **<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.01, ****<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.0001; two-tailed Student&#x02019;s t-test</p></caption><graphic xlink:href="10020_2025_1206_Fig5_HTML" id="d33e1132"/></fig>
</p><p id="Par67">Meanwhile, we assessed the IC<sub>50</sub> values of 5-FU after the use of Met (0.5mM) after IR, which were significantly reduced by Met (Fig.&#x000a0;<xref rid="Fig5" ref-type="fig">5</xref>F-G). Similar results were found in cells overexpressing GGH<sub>&#x02212;&#x00394;N</sub> (Fig.&#x000a0;<xref rid="Fig5" ref-type="fig">5</xref>H-I). We conducted drug sensitivity assays to further investigate the synergistic effect of Met and 5-FU. And the highest single agent (HSA) score was 13.069, indicating an obvious synergistic effect. Collectively, which indicate that Met amplifies the cytotoxicity of 5-FU in cells after IR (Fig.&#x000a0;<xref rid="Fig5" ref-type="fig">5</xref>J-K). Furthermore, 5-FU&#x02009;+&#x02009;Met substantially inhibited colony formation in HCT-15 cells after IR (Fig.&#x000a0;<xref rid="Fig5" ref-type="fig">5</xref>L-M). Similarly, 5-FU&#x02009;+&#x02009;Met substantially inhibited wound healing in HCT-15 cells after IR (Fig.&#x000a0;<xref rid="Fig5" ref-type="fig">5</xref>N-O). In conclusion, these results establish the central role of 5-FU&#x02009;+&#x02009;Met in CRC progression.</p></sec><sec id="Sec28"><title>5-FU-resistance can be overcome by the combination of Met in vivo</title><p id="Par68">The subcutaneous HCT-15 tumor model was established in nude mouse, and which were divided into sham IR group and IR (Fig.&#x000a0;<xref rid="Fig6" ref-type="fig">6</xref>A). The IR group was further divided into several subgroups: sham Drug, 5-FU, Met, and 5-FU combined with Met (Fig.&#x000a0;<xref rid="Fig6" ref-type="fig">6</xref>A).</p><p id="Par69">
<fig id="Fig6"><label>Fig. 6</label><caption><p> 5-FU-resistance can be overcome by the combination of Met in vivo. (<bold>A</bold>) Scheme for 5-FU, Met, and combination therapy after irradiation treatment in the HCT-15-injection nude mouse. (<bold>B-D</bold>) Levels 5,10-CH<sub>2</sub>-H<sub>4</sub>PteGlu<sub>n</sub> in IR group and sham IR group HCT-15-injection nude mouse. Various types of 5,10-CH<sub>2</sub>-H<sub>4</sub>PteGlu<sub>n</sub> (<bold>B</bold>); Total 5,10-CH<sub>2</sub>-H<sub>4</sub>PteGlu (<bold>C</bold>); Proportion analysis of various types of 5,10-CH<sub>2</sub>-H<sub>4</sub>PteGlu (<bold>D</bold>). (<bold>E</bold>) Endogenous GGH and HM13 protein expression in IR group, IR&#x02009;+&#x02009;HM13<sup>KD</sup> group and sham IR group HCT-15-injection nude mouse. (<italic>n</italic>&#x02009;=&#x02009;4). (<bold>F-H</bold>) Growth curve (<bold>F</bold>) and photographs (<bold>G</bold>) of tumors collected from mice treated with 5-FU, Met or 5-FU&#x02009;+&#x02009;Met; Tumor weight at the endpoint of the in vivo experiment (<bold>H</bold>). (<bold>I-K</bold>) Growth curve (<bold>I</bold>) and photographs (<bold>J</bold>) of tumors collected from mice-irradiated (2&#x000a0;Gy &#x000d7; 8) treated with 5-FU, Met and the combination; Tumor weight at the endpoint of the in vivo experiment (<bold>K</bold>). (<italic>n</italic>&#x02009;=&#x02009;4). (<bold>L</bold>) Effect of 5-FU and Met combined therapy (post-IR Day 24). Error bars represent the SD. *<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.05, **<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.01, ***<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.001, ****<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.0001, two-tailed Student&#x02019;s t-test</p></caption><graphic xlink:href="10020_2025_1206_Fig6_HTML" id="d33e1265"/></fig>
</p><p id="Par70">First, we assessed the content of 5,10-CH<sub>2</sub>-THF in tumor tissues from mice irradiated with 2&#x000a0;Gy &#x000d7; 8, and the content of 5, 10-CH<sub>2</sub>-THF was significantly reduced in tumor tissues, consistent with our in vitro results (Fig.&#x000a0;<xref rid="Fig6" ref-type="fig">6</xref>B-D). Western blot analysis confirmed increased HM13 expression, and led to a downward shift in the GGH protein band in IR group (Fig.&#x000a0;<xref rid="Fig6" ref-type="fig">6</xref>E). We found that there was no obvious synergistic effect between 5-FU and Met in sham IR group. (Fig.&#x000a0;<xref rid="Fig6" ref-type="fig">6</xref>F-H, Fig S8A-B). In contrast, our results showed that 5-FU&#x02009;+&#x02009;Met significantly blocked CRC growth in vivo after the indicated IR which corroborated the in vitro findings (Fig.&#x000a0;<xref rid="Fig6" ref-type="fig">6</xref>I-L, Fig S8C). The possible reason is that the GGH protein in sham IR group functioned normally and was located in the lysosome. There is sufficient 5,10-CH<sub>2</sub>-THF in cells to combine with FdUMP, to form ternary complexes, so the supply of folate pool provided by metformin does not effectively increase the cytotoxicity of 5-FU.</p></sec></sec><sec id="Sec29"><title>Discussion</title><p id="Par71">Despite recent advancements in the treatment of CRC, there has been no substantial improvement in long-term survival rates or prognosis. Hence, combining targeted therapies with surgical and radiotherapy is vital for improving the prognosis of CRC patients.</p><p id="Par72">5-FU sensitizes CRC cells to irradiation (Shewach and Lawrence <xref ref-type="bibr" rid="CR29">2007</xref>). However, increasing evidence indicates 5-FU may be noneffective after irradiation. Therefore, it is critical to investigate the potential resistance mechanism of 5-FU after irradiation in order to guide the clinical curative effect, ultimately improving the prognosis of patients with CRC.</p><p id="Par73">We performed RNA-seq on CRC cell lines irradiated and on 5-FU resistance cell lines and identified HM13 overactivation as a key influencing factor. Recent studies have reported that elevated HM13 expression correlates with poor prognosis in lung cancer, hepatocellular carcinoma, breast cancer, and glioblastoma patients (Wei et al. <xref ref-type="bibr" rid="CR30">2017</xref>; Zhang et al. <xref ref-type="bibr" rid="CR31">2022</xref>; Zhou et al. <xref ref-type="bibr" rid="CR32">2021</xref>; Yang et al. <xref ref-type="bibr" rid="CR33">2022</xref>). Further investigation of HM13 protein function and related signaling pathways should help to determine whether HM13 can be used as a potential biomarker to predict 5-FU chemotherapy resistance in colorectal cancer.</p><p id="Par74">Studies on 5-FU resistance continues to be a central focus. Recently, several studies have reported that Nano-formulated drug delivery of 5-FU can enhance the therapeutic effect of 5-FU. Folic-acid conjugated liposomes of 5-FU might increase the therapeutic efficacy of drug whereas the toxic side effects have been decreased; the nanoscale fluoropyrimidine polymer (CF10) might be effective at inhibiting CRC metastatic progression (Sah et al. <xref ref-type="bibr" rid="CR34">2023</xref>; Sethy and Kundu <xref ref-type="bibr" rid="CR35">2021</xref>). In addition, strategies targeting cell surface or intracellular receptors are emerging as valuable approaches to reverse existing resistance mechanisms (Sah et al. <xref ref-type="bibr" rid="CR36">2024</xref>). Given that 5-FU is an antimetabolite drug and HM13 is involved in the maturation of metabolically relevant exoenzymes, we focused on the lesser-studied 5,10-CH<sub>2</sub>-THF in the ternary complex, a crucial component of the intracellular folate cycle. We evaluated key enzymes in the folate cycle and found that only the GGH gene contains an N-terminal signal peptide. Further analysis revealed that abnormal deletion of the GGH signal peptide forms the GGH<sub>&#x02212;&#x00394;N</sub> protein, causing GGH to localize in the cytoplasm, consistent with our previous research. Normally, GGH resides in lysosomes, where its activity is limited by lysosomal membrane transport rates, but GGH-<sub>&#x00394;N</sub> exerts its hydrolytic function directly in the cytoplasm, significantly enhancing GGH activity. This results in the hydrolysis and cellular expulsion of polyglutamylated 5,10-CH<sub>2</sub>-THF, lowering intracellular folate levels, reducing the overall folate cycle, and decreasing 5,10-CH<sub>2</sub>-THF production. Which hinders complex formation, leading to 5-FU resistance.</p><p id="Par75">The methyl trap hypothesis (5,10-CH<sub>2</sub>-THF&#x02019;s irreversible transformation into 5-CH<sub>3</sub>-THF) suggests that Met could promote the accumulation of folate in the direction of 5-CH<sub>3</sub>-THF (Mato et al. <xref ref-type="bibr" rid="CR37">2008</xref>). We also found that there was an increase in the content of 5, 10-CH<sub>2</sub>-THF. Therefore, Met can promote the formation of 5-FU ternary complex and enhance its cytotoxic effect. Met affects glucose metabolism and purine metabolism, and 5-FU affects DNA and RNA biosynthesis. The combination of Met and 5-FU can lead to the destruction of various metabolic homeostasis in cells and accelerate the apoptosis of tumor cells. However, the specific pathways by which metformin affects intermediates of folate metabolism remain unclear.</p><p id="Par76">Furthermore, our study primarily used HCT-15 cells as an experimental model, which may limit the broader applicability of our findings. To establish more comprehensive clinical relevance, subsequent studies should include validation of other CRC molecular subtypes and patient-derived samples. In addition, although our data suggest that metformin and 5-FU synergistically work well in irradiated HCT-15 cells and nude mouse models, the potential toxicity of this combination regimen remains to be further evaluated. Additionally, the direct cause of HM13 elevation following conventional fractionated irradiation warrants further investigation to more effectively address potential 5-FU resistance post-IR, our previous study also identified gene mRNA expression differences between single high-dose and fractionated radiotherapy in HCC (Zhao et al. <xref ref-type="bibr" rid="CR38">2023</xref>). Therefore, we hypothesized that the mRNA expression of HM13 may be related to the irradiation frequency, indicating the need for further research on the different effects of activation of signaling pathways, cell metabolism and the immune microenvironment of varying dose fractionations under equivalent BED conditions.</p><p id="Par77">We revealed that IR drives an axis of 5-FU resistance (HM13-GGH-5,10-CH<sub>2</sub>-THF axis), and that Met increases the intracellular 5,10-CH<sub>2</sub>-THF concentration, which enhances the cytotoxic effects of 5-FU, reveal a new mechanism by which metformin promotes the efficacy of 5-FU, helping to expand the indication of metformin. Therefore, we propose a strategy to counteract 5-FU resistance following irradiation and demonstrate the potential mechanism, providing guidance for post-radiotherapy chemotherapy regimens.</p></sec><sec id="Sec30"><title>Conclusion</title><p id="Par78">Our study suggests that the HM13-GGH-5,10-CH<sub>2</sub>-THF axis leads to 5-FU resistance after IR (2&#x000a0;Gy &#x000d7; 8), and the combination therapy of Met and 5-FU may be a potential effective method to address drug resistance after radiotherapy. In summary, our study will help to reveal the mechanisms of IR-induced 5-FU resistance, which is important for finding new therapeutic targets and improving the efficacy of chemotherapy regimens after radiotherapy.</p></sec><sec id="Sec32" sec-type="supplementary-material"><title>Electronic supplementary material</title><p>Below is the link to the electronic supplementary material.</p><p>
<supplementary-material content-type="local-data" id="MOESM1"><media xlink:href="10020_2025_1206_MOESM1_ESM.docx"><caption><p>Supplementary Material 1</p></caption></media></supplementary-material>
</p></sec></body><back><fn-group><fn><p><bold>Publisher&#x02019;s note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn><fn><p>Shuxuan Wang and Yanyan Lin equally contributed to this work.</p></fn></fn-group><ack><title>Acknowledgements</title><p>We are very grateful to Zhenyu Zhang, Wenji Zhu and Wenchao Zhu for this excellent technical assistance.</p></ack><notes notes-type="author-contribution"><title>Author contributions</title><p>SXW, YYL and ZCZ conceptualized and designed the study. SXW, YYL, QQZ, HLC and SSD conducted the data analysis. SXW and YYL drafted the original manuscript. SXW and ZCZ critically reviewed and edited the paper. ZCZ provided supervision throughout the project. All authors have thoroughly reviewed and approved the final version of the manuscript for publication.</p></notes><notes notes-type="funding-information"><title>Funding</title><p>This work was supported by grants from the National Key Research and Development Program of China (2022YFC2503704); The National Natural Science Foundation of China (82102823, 82373519); The China Postdoctoral Science Foundation (2021M700832).</p></notes><notes notes-type="data-availability"><title>Data availability</title><p>The RNA-seq data generated in this study is available in SRA under accession number PRJNA1197681. Other data that support the findings of this study are available from the corresponding author upon request (zeng.zhaochong@zs-hospital.sh.cn). Method section described all the data used for analysis in this study.</p></notes><notes><title><bold>Ethics declarations</bold></title><notes id="FPar1"><title>Ethics approval and consent to participate</title><p id="Par80">All animal studies were approved by the Animal Ethics Committee of Zhongshan Hospital, Fudan University, and conducted in accordance with the Guide for the Care and Use of Laboratory Animals.</p></notes><notes id="FPar2"><title>Consent for publication</title><p id="Par81">Not applicable.</p></notes><notes id="FPar3" notes-type="COI-statement"><title>Competing interests</title><p id="Par82">The authors declare no competing interests.</p></notes></notes><glossary><title>Abbreviations</title><def-list><def-item><term>CRC</term><def><p id="Par83">Colorectal cancer</p></def></def-item><def-item><term>DDR</term><def><p id="Par84">DNA damage repair</p></def></def-item><def-item><term>dNTP</term><def><p id="Par85">Deoxynucleoside triphosphate</p></def></def-item><def-item><term>dTMP</term><def><p id="Par86">Deoxythymidine monophosphate</p></def></def-item><def-item><term>dTTP</term><def><p id="Par87">Deoxythymidine triphosphate</p></def></def-item><def-item><term>dUMP</term><def><p id="Par88">2&#x02032;-deoxyuridine-5&#x02032;-monophosphate</p></def></def-item><def-item><term>dUTP</term><def><p id="Par89">Deoxyuridine triphosphate</p></def></def-item><def-item><term>FdUMP</term><def><p id="Par90">5-fluoro-2&#x02019;-deoxyuridylate monophosphate</p></def></def-item><def-item><term>GGH</term><def><p id="Par91">&#x003b3;-Glutamyl Hydrolase</p></def></def-item><def-item><term>GTEx</term><def><p id="Par92">Genotype-Tissue Expression</p></def></def-item><def-item><term>HM13</term><def><p id="Par93">Histocompatibility Minor 13</p></def></def-item><def-item><term>HSA</term><def><p id="Par94">Highest single agent</p></def></def-item><def-item><term>IC<sub>50</sub></term><def><p id="Par95">The half-maximal inhibitory concentration</p></def></def-item><def-item><term>IMP</term><def><p id="Par96">Inosine monophosphate</p></def></def-item><def-item><term>LV</term><def><p id="Par97">Leucovorin</p></def></def-item><def-item><term>Met</term><def><p id="Par98">Metformin</p></def></def-item><def-item><term>MTX</term><def><p id="Par99">Methotrexate</p></def></def-item><def-item><term>OS</term><def><p id="Par100">Overall survival</p></def></def-item><def-item><term>RNA-seq</term><def><p id="Par101">RNA-sequencing</p></def></def-item><def-item><term>RT</term><def><p id="Par102">Radiation therapy</p></def></def-item><def-item><term>SSs</term><def><p id="Par103">Signal sequences</p></def></def-item><def-item><term>TCGA</term><def><p id="Par104">The Cancer Genome Atlas</p></def></def-item><def-item><term>TS</term><def><p id="Par105">Thymidylate synthase</p></def></def-item><def-item><term>5-CH<sub>3</sub>-THF</term><def><p id="Par106">5-methyl-tetrahydrofolate</p></def></def-item><def-item><term>5-FdUTP</term><def><p id="Par107">5-fluoro-2&#x02019;-deoxyuridine triphosphate</p></def></def-item><def-item><term>5-FU</term><def><p id="Par108">5-fluorouracil</p></def></def-item><def-item><term>5,10-CH<sub>2</sub>-THF</term><def><p id="Par109">5, 10-methylenetetrahydrofolate</p></def></def-item></def-list></glossary><ref-list id="Bib1"><title>References</title><ref id="CR12"><citation-alternatives><element-citation id="ec-CR12" publication-type="journal"><person-group person-group-type="author"><name><surname>Acharya</surname><given-names>G</given-names></name><name><surname>Mani</surname><given-names>C</given-names></name><name><surname>Sah</surname><given-names>N</given-names></name><etal/></person-group><article-title>CHK1 inhibitor induced parylation by targeting PARG causes excessive replication and metabolic stress and overcomes chemoresistance in ovarian cancer</article-title><source>Cell Death Discov Jun</source><year>2024</year><volume>11</volume><issue>1</issue><fpage>278</fpage><pub-id pub-id-type="doi">10.1038/s41420-024-02040-0</pub-id></element-citation><mixed-citation id="mc-CR12" publication-type="journal">Acharya G, Mani C, Sah N, et al. CHK1 inhibitor induced parylation by targeting PARG causes excessive replication and metabolic stress and overcomes chemoresistance in ovarian cancer. Cell Death Discov Jun. 2024;11(1):278. 10.1038/s41420-024-02040-0.</mixed-citation></citation-alternatives></ref><ref id="CR13"><citation-alternatives><element-citation id="ec-CR13" publication-type="journal"><person-group person-group-type="author"><name><surname>Ahmad</surname><given-names>SS</given-names></name><name><surname>Duke</surname><given-names>S</given-names></name><name><surname>Jena</surname><given-names>R</given-names></name><name><surname>Williams</surname><given-names>MV</given-names></name><name><surname>Burnet</surname><given-names>NG</given-names></name></person-group><article-title>Advances in radiotherapy</article-title><source>BMJ</source><year>2012</year><volume>345</volume><issue>04 1</issue><fpage>e7765</fpage><lpage>7765</lpage><pub-id pub-id-type="doi">10.1136/bmj.e7765</pub-id><pub-id pub-id-type="pmid">23212681</pub-id>
</element-citation><mixed-citation id="mc-CR13" publication-type="journal">Ahmad SS, Duke S, Jena R, Williams MV, Burnet NG. Advances in radiotherapy. BMJ. 2012;345(04 1):e7765&#x02013;7765. 10.1136/bmj.e7765.<pub-id pub-id-type="pmid">23212681</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR7"><citation-alternatives><element-citation id="ec-CR7" publication-type="journal"><person-group person-group-type="author"><name><surname>Bosset</surname><given-names>JF</given-names></name><name><surname>Calais</surname><given-names>G</given-names></name><name><surname>Mineur</surname><given-names>L</given-names></name><etal/></person-group><article-title>Fluorouracil-based adjuvant chemotherapy after preoperative chemoradiotherapy in rectal cancer: long-term results of the EORTC 22921 randomised study</article-title><source>Lancet Oncol Feb</source><year>2014</year><volume>15</volume><issue>2</issue><fpage>184</fpage><lpage>90</lpage><pub-id pub-id-type="doi">10.1016/S1470-2045(13)70599-0</pub-id></element-citation><mixed-citation id="mc-CR7" publication-type="journal">Bosset JF, Calais G, Mineur L, et al. Fluorouracil-based adjuvant chemotherapy after preoperative chemoradiotherapy in rectal cancer: long-term results of the EORTC 22921 randomised study. Lancet Oncol Feb. 2014;15(2):184&#x02013;90. 10.1016/S1470-2045(13)70599-0.</mixed-citation></citation-alternatives></ref><ref id="CR28"><citation-alternatives><element-citation id="ec-CR28" publication-type="journal"><person-group person-group-type="author"><name><surname>Cabreiro</surname><given-names>F</given-names></name><name><surname>Au</surname><given-names>C</given-names></name><name><surname>Leung</surname><given-names>KY</given-names></name><etal/></person-group><article-title>Metformin retards aging in C. elegans by altering microbial folate and methionine metabolism</article-title><source>Cell Mar 28</source><year>2013</year><volume>153</volume><issue>1</issue><fpage>228</fpage><lpage>39</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2013.02.035</pub-id></element-citation><mixed-citation id="mc-CR28" publication-type="journal">Cabreiro F, Au C, Leung KY, et al. Metformin retards aging in C. elegans by altering microbial folate and methionine metabolism. Cell Mar 28. 2013;153(1):228&#x02013;39. 10.1016/j.cell.2013.02.035.</mixed-citation></citation-alternatives></ref><ref id="CR25"><citation-alternatives><element-citation id="ec-CR25" publication-type="journal"><person-group person-group-type="author"><name><surname>Corominas-Faja</surname><given-names>B</given-names></name><name><surname>Quirantes-Pine</surname><given-names>R</given-names></name><name><surname>Oliveras-Ferraros</surname><given-names>C</given-names></name><etal/></person-group><article-title>Metabolomic fingerprint reveals that Metformin impairs one-carbon metabolism in a manner similar to the antifolate class of chemotherapy drugs</article-title><source>Aging (Albany NY) Jul</source><year>2012</year><volume>4</volume><issue>7</issue><fpage>480</fpage><lpage>98</lpage><pub-id pub-id-type="doi">10.18632/aging.100472</pub-id></element-citation><mixed-citation id="mc-CR25" publication-type="journal">Corominas-Faja B, Quirantes-Pine R, Oliveras-Ferraros C, et al. Metabolomic fingerprint reveals that Metformin impairs one-carbon metabolism in a manner similar to the antifolate class of chemotherapy drugs. Aging (Albany NY) Jul. 2012;4(7):480&#x02013;98. 10.18632/aging.100472.</mixed-citation></citation-alternatives></ref><ref id="CR15"><citation-alternatives><element-citation id="ec-CR15" publication-type="journal"><person-group person-group-type="author"><name><surname>Coyle</surname><given-names>C</given-names></name><name><surname>Cafferty</surname><given-names>FH</given-names></name><name><surname>Vale</surname><given-names>C</given-names></name><name><surname>Langley</surname><given-names>RE</given-names></name></person-group><article-title>Metformin as an adjuvant treatment for cancer: a systematic review and meta-analysis</article-title><source>Ann Oncol</source><year>2016</year><volume>27</volume><issue>12</issue><fpage>2184</fpage><lpage>95</lpage><pub-id pub-id-type="doi">10.1093/annonc/mdw410</pub-id><pub-id pub-id-type="pmid">27681864</pub-id>
</element-citation><mixed-citation id="mc-CR15" publication-type="journal">Coyle C, Cafferty FH, Vale C, Langley RE. Metformin as an adjuvant treatment for cancer: a systematic review and meta-analysis. Ann Oncol. 2016;27(12):2184&#x02013;95. 10.1093/annonc/mdw410.<pub-id pub-id-type="pmid">27681864</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR1"><citation-alternatives><element-citation id="ec-CR1" publication-type="journal"><person-group person-group-type="author"><name><surname>Dekker</surname><given-names>E</given-names></name><name><surname>Tanis</surname><given-names>PJ</given-names></name><name><surname>Vleugels</surname><given-names>JLA</given-names></name><name><surname>Kasi</surname><given-names>PM</given-names></name><name><surname>Wallace</surname><given-names>MB</given-names></name></person-group><article-title>Colorectal cancer</article-title><source>Lancet</source><year>2019</year><volume>394</volume><issue>10207</issue><fpage>1467</fpage><lpage>80</lpage><pub-id pub-id-type="doi">10.1016/s0140-6736(19)32319-0</pub-id><pub-id pub-id-type="pmid">31631858</pub-id>
</element-citation><mixed-citation id="mc-CR1" publication-type="journal">Dekker E, Tanis PJ, Vleugels JLA, Kasi PM, Wallace MB. Colorectal cancer. Lancet. 2019;394(10207):1467&#x02013;80. 10.1016/s0140-6736(19)32319-0.<pub-id pub-id-type="pmid">31631858</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR3"><citation-alternatives><element-citation id="ec-CR3" publication-type="journal"><person-group person-group-type="author"><name><surname>Du</surname><given-names>S</given-names></name><name><surname>Chen</surname><given-names>G</given-names></name><name><surname>Yuan</surname><given-names>B</given-names></name><etal/></person-group><article-title>DNA sensing and associated type 1 interferon signaling contributes to progression of radiation-induced liver injury</article-title><source>Cell Mol Immunol Jul</source><year>2021</year><volume>18</volume><issue>7</issue><fpage>1718</fpage><lpage>28</lpage><pub-id pub-id-type="doi">10.1038/s41423-020-0395-x</pub-id></element-citation><mixed-citation id="mc-CR3" publication-type="journal">Du S, Chen G, Yuan B, et al. DNA sensing and associated type 1 interferon signaling contributes to progression of radiation-induced liver injury. Cell Mol Immunol Jul. 2021;18(7):1718&#x02013;28. 10.1038/s41423-020-0395-x.</mixed-citation></citation-alternatives></ref><ref id="CR17"><citation-alternatives><element-citation id="ec-CR17" publication-type="journal"><person-group person-group-type="author"><name><surname>Garratt</surname><given-names>LC</given-names></name><name><surname>Ortori</surname><given-names>CA</given-names></name><name><surname>Tucker</surname><given-names>GA</given-names></name><name><surname>Sablitzky</surname><given-names>F</given-names></name><name><surname>Bennett</surname><given-names>MJ</given-names></name><name><surname>Barrett</surname><given-names>DA</given-names></name></person-group><article-title>Comprehensive metabolic profiling of mono- and polyglutamated folates and their precursors in plant and animal tissue using liquid chromatography/negative ion electrospray ionisation tandem mass spectrometry</article-title><source>Rapid Commun Mass Spectrom</source><year>2005</year><volume>19</volume><issue>17</issue><fpage>2390</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1002/rcm.2074</pub-id><pub-id pub-id-type="pmid">16047318</pub-id>
</element-citation><mixed-citation id="mc-CR17" publication-type="journal">Garratt LC, Ortori CA, Tucker GA, Sablitzky F, Bennett MJ, Barrett DA. Comprehensive metabolic profiling of mono- and polyglutamated folates and their precursors in plant and animal tissue using liquid chromatography/negative ion electrospray ionisation tandem mass spectrometry. Rapid Commun Mass Spectrom. 2005;19(17):2390&#x02013;8. 10.1002/rcm.2074.<pub-id pub-id-type="pmid">16047318</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR19"><mixed-citation publication-type="other">Gyorffy B. Integrated analysis of public datasets for the discovery and validation of survival-associated genes in solid tumors. <italic>Innovation (Camb)</italic>. 2024;5(3):100625. 10.1016/j.xinn.2024.100625</mixed-citation></ref><ref id="CR5"><citation-alternatives><element-citation id="ec-CR5" publication-type="journal"><person-group person-group-type="author"><name><surname>Haviland</surname><given-names>JS</given-names></name><name><surname>Owen</surname><given-names>JR</given-names></name><name><surname>Dewar</surname><given-names>JA</given-names></name><etal/></person-group><article-title>The UK standardisation of breast radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10-year follow-up results of two randomised controlled trials</article-title><source>Lancet Oncol Oct</source><year>2013</year><volume>14</volume><issue>11</issue><fpage>1086</fpage><lpage>94</lpage><pub-id pub-id-type="doi">10.1016/S1470-2045(13)70386-3</pub-id></element-citation><mixed-citation id="mc-CR5" publication-type="journal">Haviland JS, Owen JR, Dewar JA, et al. The UK standardisation of breast radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10-year follow-up results of two randomised controlled trials. Lancet Oncol Oct. 2013;14(11):1086&#x02013;94. 10.1016/S1470-2045(13)70386-3.</mixed-citation></citation-alternatives></ref><ref id="CR26"><citation-alternatives><element-citation id="ec-CR26" publication-type="journal"><person-group person-group-type="author"><name><surname>Janzer</surname><given-names>A</given-names></name><name><surname>German</surname><given-names>NJ</given-names></name><name><surname>Gonzalez-Herrera</surname><given-names>KN</given-names></name><name><surname>Asara</surname><given-names>JM</given-names></name><name><surname>Haigis</surname><given-names>MC</given-names></name><name><surname>Struhl</surname><given-names>K</given-names></name></person-group><article-title>Metformin and phenformin deplete Tricarboxylic acid cycle and glycolytic intermediates during cell transformation and NTPs in cancer stem cells</article-title><source>Proc Natl Acad Sci U S Jul</source><year>2014</year><volume>22</volume><issue>29</issue><fpage>10574</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1073/pnas.1409844111</pub-id></element-citation><mixed-citation id="mc-CR26" publication-type="journal">Janzer A, German NJ, Gonzalez-Herrera KN, Asara JM, Haigis MC, Struhl K. Metformin and phenformin deplete Tricarboxylic acid cycle and glycolytic intermediates during cell transformation and NTPs in cancer stem cells. Proc Natl Acad Sci U S Jul. 2014;22(29):10574&#x02013;9. 10.1073/pnas.1409844111.</mixed-citation></citation-alternatives></ref><ref id="CR27"><citation-alternatives><element-citation id="ec-CR27" publication-type="journal"><person-group person-group-type="author"><name><surname>Jara</surname><given-names>JA</given-names></name><name><surname>Lopez-Munoz</surname><given-names>R</given-names></name></person-group><article-title>Metformin and cancer: between the bioenergetic disturbances and the antifolate activity</article-title><source>Pharmacol Res Nov</source><year>2015</year><volume>101</volume><fpage>102</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1016/j.phrs.2015.06.014</pub-id></element-citation><mixed-citation id="mc-CR27" publication-type="journal">Jara JA, Lopez-Munoz R. Metformin and cancer: between the bioenergetic disturbances and the antifolate activity. Pharmacol Res. 2015;101:102&#x02013;8. 10.1016/j.phrs.2015.06.014.</mixed-citation></citation-alternatives></ref><ref id="CR10"><mixed-citation publication-type="other">Longley DB, Harkin DP, Johnston PG. 5-Fluorouracil: mechanisms of action and clinical strategies. <italic>Nature Reviews Cancer</italic>. 2003;3(5):330&#x02013;338. 10.1038/nrc1074.</mixed-citation></ref><ref id="CR11"><citation-alternatives><element-citation id="ec-CR11" publication-type="journal"><person-group person-group-type="author"><name><surname>Marsh</surname><given-names>S</given-names></name><name><surname>McKay</surname><given-names>JA</given-names></name><name><surname>Cassidy</surname><given-names>J</given-names></name><name><surname>McLeod</surname><given-names>HL</given-names></name></person-group><article-title>Polymorphism in the thymidylate synthase promoter enhancer region in colorectal cancer</article-title><source>Int J Oncol Aug</source><year>2001</year><volume>19</volume><issue>2</issue><fpage>383</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.3892/ijo.19.2.383</pub-id></element-citation><mixed-citation id="mc-CR11" publication-type="journal">Marsh S, McKay JA, Cassidy J, McLeod HL. Polymorphism in the thymidylate synthase promoter enhancer region in colorectal cancer. Int J Oncol Aug. 2001;19(2):383&#x02013;6. 10.3892/ijo.19.2.383.</mixed-citation></citation-alternatives></ref><ref id="CR37"><citation-alternatives><element-citation id="ec-CR37" publication-type="journal"><person-group person-group-type="author"><name><surname>Mato</surname><given-names>JM</given-names></name><name><surname>Martinez-Chantar</surname><given-names>ML</given-names></name><name><surname>Lu</surname><given-names>SC</given-names></name></person-group><article-title>Methionine metabolism and liver disease</article-title><source>Annu Rev Nutr</source><year>2008</year><volume>28</volume><fpage>273</fpage><lpage>93</lpage><pub-id pub-id-type="doi">10.1146/annurev.nutr.28.061807.155438</pub-id><pub-id pub-id-type="pmid">18331185</pub-id>
</element-citation><mixed-citation id="mc-CR37" publication-type="journal">Mato JM, Martinez-Chantar ML, Lu SC. Methionine metabolism and liver disease. Annu Rev Nutr. 2008;28:273&#x02013;93. 10.1146/annurev.nutr.28.061807.155438.<pub-id pub-id-type="pmid">18331185</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR2"><citation-alternatives><element-citation id="ec-CR2" publication-type="journal"><person-group person-group-type="author"><name><surname>McLaughlin</surname><given-names>M</given-names></name><name><surname>Patin</surname><given-names>EC</given-names></name><name><surname>Pedersen</surname><given-names>M</given-names></name><etal/></person-group><article-title>Inflammatory microenvironment remodelling by tumour cells after radiotherapy</article-title><source>Nat Rev Cancer Apr</source><year>2020</year><volume>20</volume><issue>4</issue><fpage>203</fpage><lpage>17</lpage><pub-id pub-id-type="doi">10.1038/s41568-020-0246-1</pub-id></element-citation><mixed-citation id="mc-CR2" publication-type="journal">McLaughlin M, Patin EC, Pedersen M, et al. Inflammatory microenvironment remodelling by tumour cells after radiotherapy. Nat Rev Cancer Apr. 2020;20(4):203&#x02013;17. 10.1038/s41568-020-0246-1.</mixed-citation></citation-alternatives></ref><ref id="CR18"><citation-alternatives><element-citation id="ec-CR18" publication-type="journal"><person-group person-group-type="author"><name><surname>Mentrup</surname><given-names>T</given-names></name><name><surname>Cabrera-Cabrera</surname><given-names>F</given-names></name><name><surname>Fluhrer</surname><given-names>R</given-names></name><name><surname>Schroder</surname><given-names>B</given-names></name></person-group><article-title>Physiological functions of SPP/SPPL intramembrane proteases</article-title><source>Cell Mol Life Sci Aug</source><year>2020</year><volume>77</volume><issue>15</issue><fpage>2959</fpage><lpage>79</lpage><pub-id pub-id-type="doi">10.1007/s00018-020-03470-6</pub-id></element-citation><mixed-citation id="mc-CR18" publication-type="journal">Mentrup T, Cabrera-Cabrera F, Fluhrer R, Schroder B. Physiological functions of SPP/SPPL intramembrane proteases. Cell Mol Life Sci Aug. 2020;77(15):2959&#x02013;79. 10.1007/s00018-020-03470-6.</mixed-citation></citation-alternatives></ref><ref id="CR21"><citation-alternatives><element-citation id="ec-CR21" publication-type="journal"><person-group person-group-type="author"><name><surname>Raz</surname><given-names>S</given-names></name><name><surname>Stark</surname><given-names>M</given-names></name><name><surname>Assaraf</surname><given-names>YG</given-names></name></person-group><article-title>Folylpoly-gamma-glutamate synthetase: A key determinant of folate homeostasis and antifolate resistance in cancer</article-title><source>Drug Resist Updat Sep</source><year>2016</year><volume>28</volume><fpage>43</fpage><lpage>64</lpage><pub-id pub-id-type="doi">10.1016/j.drup.2016.06.004</pub-id></element-citation><mixed-citation id="mc-CR21" publication-type="journal">Raz S, Stark M, Assaraf YG. Folylpoly-gamma-glutamate synthetase: A key determinant of folate homeostasis and antifolate resistance in cancer. Drug Resist Updat Sep. 2016;28:43&#x02013;64. 10.1016/j.drup.2016.06.004.</mixed-citation></citation-alternatives></ref><ref id="CR34"><citation-alternatives><element-citation id="ec-CR34" publication-type="journal"><person-group person-group-type="author"><name><surname>Sah</surname><given-names>N</given-names></name><name><surname>Luna</surname><given-names>P</given-names></name><name><surname>Mani</surname><given-names>C</given-names></name><name><surname>Gmeiner</surname><given-names>W</given-names></name><name><surname>Palle</surname><given-names>K</given-names></name></person-group><article-title>Abstract 6178: A novel second-generation nano-fluoropyrimidine to treat metastatic colorectal cancer and overcome 5-fluorouracil resistance</article-title><source>Cancer Res</source><year>2023</year><volume>83</volume><issue>7Supplement</issue><fpage>6178</fpage><lpage>6178</lpage><pub-id pub-id-type="doi">10.1158/1538-7445.am2023-6178</pub-id></element-citation><mixed-citation id="mc-CR34" publication-type="journal">Sah N, Luna P, Mani C, Gmeiner W, Palle K. Abstract 6178: A novel second-generation nano-fluoropyrimidine to treat metastatic colorectal cancer and overcome 5-fluorouracil resistance. Cancer Res. 2023;83(7Supplement):6178&#x02013;6178. 10.1158/1538-7445.am2023-6178.</mixed-citation></citation-alternatives></ref><ref id="CR36"><citation-alternatives><element-citation id="ec-CR36" publication-type="journal"><person-group person-group-type="author"><name><surname>Sah</surname><given-names>N</given-names></name><name><surname>Shaik</surname><given-names>AA</given-names></name><name><surname>Acharya</surname><given-names>G</given-names></name><etal/></person-group><article-title>Receptor-Based strategies for overcoming resistance in cancer therapy</article-title><source>Receptors</source><year>2024</year><volume>3</volume><issue>4</issue><fpage>425</fpage><lpage>43</lpage><pub-id pub-id-type="doi">10.3390/receptors3040021</pub-id></element-citation><mixed-citation id="mc-CR36" publication-type="journal">Sah N, Shaik AA, Acharya G, et al. Receptor-Based strategies for overcoming resistance in cancer therapy. Receptors. 2024;3(4):425&#x02013;43. 10.3390/receptors3040021.</mixed-citation></citation-alternatives></ref><ref id="CR8"><citation-alternatives><element-citation id="ec-CR8" publication-type="journal"><person-group person-group-type="author"><name><surname>Sainato</surname><given-names>A</given-names></name><name><surname>Cernusco Luna Nunzia</surname><given-names>V</given-names></name><name><surname>Valentini</surname><given-names>V</given-names></name><etal/></person-group><article-title>No benefit of adjuvant fluorouracil leucovorin chemotherapy after neoadjuvant chemoradiotherapy in locally advanced cancer of the rectum (LARC): long term results of a randomized trial (I-CNR-RT)</article-title><source>Radiother Oncol Nov</source><year>2014</year><volume>113</volume><issue>2</issue><fpage>223</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1016/j.radonc.2014.10.006</pub-id></element-citation><mixed-citation id="mc-CR8" publication-type="journal">Sainato A, Cernusco Luna Nunzia V, Valentini V, et al. No benefit of adjuvant fluorouracil leucovorin chemotherapy after neoadjuvant chemoradiotherapy in locally advanced cancer of the rectum (LARC): long term results of a randomized trial (I-CNR-RT). Radiother Oncol Nov. 2014;113(2):223&#x02013;9. 10.1016/j.radonc.2014.10.006.</mixed-citation></citation-alternatives></ref><ref id="CR35"><citation-alternatives><element-citation id="ec-CR35" publication-type="journal"><person-group person-group-type="author"><name><surname>Sethy</surname><given-names>C</given-names></name><name><surname>Kundu</surname><given-names>CN</given-names></name></person-group><article-title>5-Fluorouracil (5-FU) resistance and the new strategy to enhance the sensitivity against cancer: implication of DNA repair Inhibition</article-title><source>Biomed Pharmacother</source><year>2021</year><volume>137</volume><fpage>111285</fpage><pub-id pub-id-type="doi">10.1016/j.biopha.2021.111285</pub-id><pub-id pub-id-type="pmid">33485118</pub-id>
</element-citation><mixed-citation id="mc-CR35" publication-type="journal">Sethy C, Kundu CN. 5-Fluorouracil (5-FU) resistance and the new strategy to enhance the sensitivity against cancer: implication of DNA repair Inhibition. Biomed Pharmacother. 2021;137:111285. 10.1016/j.biopha.2021.111285.<pub-id pub-id-type="pmid">33485118</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR20"><citation-alternatives><element-citation id="ec-CR20" publication-type="journal"><person-group person-group-type="author"><name><surname>Shen</surname><given-names>W</given-names></name><name><surname>Song</surname><given-names>Z</given-names></name><name><surname>Zhong</surname><given-names>X</given-names></name><etal/></person-group><article-title>Sangerbox: A comprehensive, interaction-friendly clinical bioinformatics analysis platform</article-title><source>Commentary iMeta</source><year>2022</year><volume>1</volume><issue>3</issue><fpage>e36</fpage><pub-id pub-id-type="doi">10.1002/imt2.36</pub-id></element-citation><mixed-citation id="mc-CR20" publication-type="journal">Shen W, Song Z, Zhong X, et al. Sangerbox: A comprehensive, interaction-friendly clinical bioinformatics analysis platform. Commentary iMeta. 2022;1(3):e36. 10.1002/imt2.36. /07/08 2022.</mixed-citation></citation-alternatives></ref><ref id="CR29"><citation-alternatives><element-citation id="ec-CR29" publication-type="journal"><person-group person-group-type="author"><name><surname>Shewach</surname><given-names>DS</given-names></name><name><surname>Lawrence</surname><given-names>TS</given-names></name></person-group><article-title>Antimetabolite radiosensitizers</article-title><source>J Clin Oncol Sep</source><year>2007</year><volume>10</volume><issue>26</issue><fpage>4043</fpage><lpage>50</lpage><pub-id pub-id-type="doi">10.1200/JCO.2007.11.5287</pub-id></element-citation><mixed-citation id="mc-CR29" publication-type="journal">Shewach DS, Lawrence TS. Antimetabolite radiosensitizers. J Clin Oncol Sep. 2007;10(26):4043&#x02013;50. 10.1200/JCO.2007.11.5287.</mixed-citation></citation-alternatives></ref><ref id="CR9"><citation-alternatives><element-citation id="ec-CR9" publication-type="journal"><person-group person-group-type="author"><name><surname>Tang</surname><given-names>M</given-names></name><name><surname>Lu</surname><given-names>X</given-names></name><name><surname>Zhang</surname><given-names>C</given-names></name><etal/></person-group><article-title>Downregulation of SIRT7 by 5-fluorouracil induces radiosensitivity in human colorectal cancer</article-title><source>Theranostics</source><year>2017</year><volume>7</volume><issue>5</issue><fpage>1346</fpage><lpage>59</lpage><pub-id pub-id-type="doi">10.7150/thno.18804</pub-id><pub-id pub-id-type="pmid">28435470</pub-id>
</element-citation><mixed-citation id="mc-CR9" publication-type="journal">Tang M, Lu X, Zhang C, et al. Downregulation of SIRT7 by 5-fluorouracil induces radiosensitivity in human colorectal cancer. Theranostics. 2017;7(5):1346&#x02013;59. 10.7150/thno.18804.<pub-id pub-id-type="pmid">28435470</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR16"><mixed-citation publication-type="other">Teufel F, Almagro Armenteros JJ, Johansen AR et al. SignalP 6.0 predicts all five types of signal peptides using protein language models. <italic>Nature Biotechnology</italic>. 2022;40(7):1023&#x02013;1025. 10.1038/s41587-021-01156-3</mixed-citation></ref><ref id="CR4"><citation-alternatives><element-citation id="ec-CR4" publication-type="journal"><person-group person-group-type="author"><name><surname>Tsai</surname><given-names>M-H</given-names></name><name><surname>Cook</surname><given-names>JA</given-names></name><name><surname>Chandramouli</surname><given-names>GVR</given-names></name><etal/></person-group><article-title>Gene expression profiling of breast, prostate, and glioma cells following single versus fractionated doses of radiation</article-title><source>Cancer Res</source><year>2007</year><volume>67</volume><issue>8</issue><fpage>3845</fpage><lpage>52</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.Can-06-4250</pub-id><pub-id pub-id-type="pmid">17440099</pub-id>
</element-citation><mixed-citation id="mc-CR4" publication-type="journal">Tsai M-H, Cook JA, Chandramouli GVR, et al. Gene expression profiling of breast, prostate, and glioma cells following single versus fractionated doses of radiation. Cancer Res. 2007;67(8):3845&#x02013;52. 10.1158/0008-5472.Can-06-4250.<pub-id pub-id-type="pmid">17440099</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR22"><citation-alternatives><element-citation id="ec-CR22" publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>S</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Fang</surname><given-names>H</given-names></name><etal/></person-group><article-title>A &#x003b3;-glutamyl hydrolase lacking the signal peptide confers susceptibility to folates/antifolates in acute lymphoblastic leukemia cells</article-title><source>FEBS Lett</source><year>2022</year><volume>596</volume><issue>4</issue><fpage>437</fpage><lpage>48</lpage><pub-id pub-id-type="doi">10.1002/1873-3468.14285</pub-id><pub-id pub-id-type="pmid">35040120</pub-id>
</element-citation><mixed-citation id="mc-CR22" publication-type="journal">Wang S, Chen Y, Fang H, et al. A &#x003b3;-glutamyl hydrolase lacking the signal peptide confers susceptibility to folates/antifolates in acute lymphoblastic leukemia cells. FEBS Lett. 2022;596(4):437&#x02013;48. 10.1002/1873-3468.14285.<pub-id pub-id-type="pmid">35040120</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR30"><citation-alternatives><element-citation id="ec-CR30" publication-type="journal"><person-group person-group-type="author"><name><surname>Wei</surname><given-names>JW</given-names></name><name><surname>Cai</surname><given-names>JQ</given-names></name><name><surname>Fang</surname><given-names>C</given-names></name><etal/></person-group><article-title>Signal peptide peptidase, encoded by HM13, contributes to tumor progression by affecting EGFRvIII secretion profiles in glioblastoma</article-title><source>CNS Neurosci Ther Mar</source><year>2017</year><volume>23</volume><issue>3</issue><fpage>257</fpage><lpage>65</lpage><pub-id pub-id-type="doi">10.1111/cns.12672</pub-id></element-citation><mixed-citation id="mc-CR30" publication-type="journal">Wei JW, Cai JQ, Fang C, et al. Signal peptide peptidase, encoded by HM13, contributes to tumor progression by affecting EGFRvIII secretion profiles in glioblastoma. CNS Neurosci Ther Mar. 2017;23(3):257&#x02013;65. 10.1111/cns.12672.</mixed-citation></citation-alternatives></ref><ref id="CR33"><citation-alternatives><element-citation id="ec-CR33" publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>H</given-names></name><name><surname>Li</surname><given-names>Z</given-names></name><name><surname>Wang</surname><given-names>Z</given-names></name><etal/></person-group><article-title>Histocompatibility minor 13 (HM13), targeted by miR-760, exerts oncogenic role in breast cancer by suppressing autophagy and activating PI3K-AKT-mTOR pathway</article-title><source>Cell Death Dis Sep</source><year>2022</year><volume>25</volume><issue>8</issue><fpage>728</fpage><pub-id pub-id-type="doi">10.1038/s41419-022-05154-4</pub-id></element-citation><mixed-citation id="mc-CR33" publication-type="journal">Yang H, Li Z, Wang Z, et al. Histocompatibility minor 13 (HM13), targeted by miR-760, exerts oncogenic role in breast cancer by suppressing autophagy and activating PI3K-AKT-mTOR pathway. Cell Death Dis Sep. 2022;25(8):728. 10.1038/s41419-022-05154-4.</mixed-citation></citation-alternatives></ref><ref id="CR23"><citation-alternatives><element-citation id="ec-CR23" publication-type="journal"><person-group person-group-type="author"><name><surname>Yao</surname><given-names>R</given-names></name><name><surname>Nimec</surname><given-names>Z</given-names></name><name><surname>Ryan</surname><given-names>TJ</given-names></name><name><surname>Galivan</surname><given-names>J</given-names></name></person-group><article-title>Identification, cloning, and sequencing of a cDNA coding for rat gamma-glutamyl hydrolase</article-title><source>J Biol Chem Apr</source><year>1996</year><volume>12</volume><issue>15</issue><fpage>8525</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1074/jbc.271.15.8525</pub-id></element-citation><mixed-citation id="mc-CR23" publication-type="journal">Yao R, Nimec Z, Ryan TJ, Galivan J. Identification, cloning, and sequencing of a cDNA coding for rat gamma-glutamyl hydrolase. J Biol Chem Apr. 1996a;12(15):8525&#x02013;8. 10.1074/jbc.271.15.8525.</mixed-citation></citation-alternatives></ref><ref id="CR24"><citation-alternatives><element-citation id="ec-CR24" publication-type="journal"><person-group person-group-type="author"><name><surname>Yao</surname><given-names>R</given-names></name><name><surname>Schneider</surname><given-names>E</given-names></name><name><surname>Ryan</surname><given-names>TJ</given-names></name><name><surname>Galivan</surname><given-names>J</given-names></name></person-group><article-title>Human gamma-glutamyl hydrolase: cloning and characterization of the enzyme expressed in vitro</article-title><source>Proc Natl Acad Sci U S Sep</source><year>1996</year><volume>17</volume><issue>19</issue><fpage>10134</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1073/pnas.93.19.10134</pub-id></element-citation><mixed-citation id="mc-CR24" publication-type="journal">Yao R, Schneider E, Ryan TJ, Galivan J. Human gamma-glutamyl hydrolase: cloning and characterization of the enzyme expressed in vitro. Proc Natl Acad Sci U S Sep. 1996b;17(19):10134&#x02013;8. 10.1073/pnas.93.19.10134.</mixed-citation></citation-alternatives></ref><ref id="CR31"><citation-alternatives><element-citation id="ec-CR31" publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>G</given-names></name><name><surname>Lv</surname><given-names>X</given-names></name><name><surname>Yang</surname><given-names>Q</given-names></name><name><surname>Liu</surname><given-names>H</given-names></name></person-group><article-title>Identification of HM13 as a prognostic indicator and a predictive biomarker for immunotherapy in hepatocellular carcinoma</article-title><source>BMC Cancer Aug</source><year>2022</year><volume>13</volume><issue>1</issue><fpage>888</fpage><pub-id pub-id-type="doi">10.1186/s12885-022-09987-2</pub-id></element-citation><mixed-citation id="mc-CR31" publication-type="journal">Zhang G, Lv X, Yang Q, Liu H. Identification of HM13 as a prognostic indicator and a predictive biomarker for immunotherapy in hepatocellular carcinoma. BMC Cancer Aug. 2022;13(1):888. 10.1186/s12885-022-09987-2.</mixed-citation></citation-alternatives></ref><ref id="CR38"><citation-alternatives><element-citation id="ec-CR38" publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>X</given-names></name><name><surname>Wang</surname><given-names>B</given-names></name><name><surname>Zhuang</surname><given-names>Y</given-names></name><name><surname>Du</surname><given-names>S</given-names></name><name><surname>Zeng</surname><given-names>Z</given-names></name></person-group><article-title>Single High-Dose Irradiation-Induced iRhom2 upregulation promotes macrophage antitumor activity through cGAS/STING signaling</article-title><source>Int J Radiat Oncol Biol Phys Aug</source><year>2023</year><volume>1</volume><issue>5</issue><fpage>1150</fpage><lpage>62</lpage><pub-id pub-id-type="doi">10.1016/j.ijrobp.2023.02.013</pub-id></element-citation><mixed-citation id="mc-CR38" publication-type="journal">Zhao X, Wang B, Zhuang Y, Du S, Zeng Z. Single High-Dose Irradiation-Induced iRhom2 upregulation promotes macrophage antitumor activity through cGAS/STING signaling. Int J Radiat Oncol Biol Phys Aug. 2023;1(5):1150&#x02013;62. 10.1016/j.ijrobp.2023.02.013.</mixed-citation></citation-alternatives></ref><ref id="CR32"><citation-alternatives><element-citation id="ec-CR32" publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>J</given-names></name><name><surname>Cheng</surname><given-names>T</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><etal/></person-group><article-title>Epigenetic imprinting alterations as effective diagnostic biomarkers for early-stage lung cancer and small pulmonary nodules</article-title><source>Clin Epigenetics Dec</source><year>2021</year><volume>14</volume><issue>1</issue><fpage>220</fpage><pub-id pub-id-type="doi">10.1186/s13148-021-01203-5</pub-id></element-citation><mixed-citation id="mc-CR32" publication-type="journal">Zhou J, Cheng T, Li X, et al. Epigenetic imprinting alterations as effective diagnostic biomarkers for early-stage lung cancer and small pulmonary nodules. Clin Epigenetics Dec. 2021;14(1):220. 10.1186/s13148-021-01203-5.</mixed-citation></citation-alternatives></ref></ref-list></back></article>